Teva to divest Teva-Takeda business venture in Japan to JKI

Teva Pharmaceutical (NYSE:TEVA) announced that it will divest Teva-Takeda, its business venture in Japan, to JKI Co., established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd.
As per the deal, all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd. will be transferred to JKI.
The divestment, which includes generics and legacy products, will allow Teva to focus on bringing its innovative medicines to the Japanese market.
The divestment aligns with Teva’s Pivot to Growth strategy to focus its business.
The deal is expected to complete by April 1, 2025.
All the employees of the business venture in Japan will remain employed, subject to the terms of the agreement.

Tags: TEVA